跳至主要内容
临床试验/JPRN-UMIN000051549
JPRN-UMIN000051549招募中Unknown

Prospective interventional clinical study to evaluate the efficacy and safety of atezolizumab plus bevacizumab in combination with carbon ion radiotherapy for unresectable hepatocellular carcinoma - Prospective interventional clinical study to evaluate the efficacy and safety of atezolizumab plus bevacizumab in combination with carbon ion radiotherapy for unresectable hepatocellular carcinoma

Yamagata University0 个研究点目标入组 20 人开始时间: 2023年7月7日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients with untreated or poorly treated esophageal aneurysms and/or gastric varices with or judged to be at high risk for bleeding. Patients who have undergone esophagogastroduodenoscopy (EGD) prior to enrollment, have been examined and treated for varices, and have been determined to be at low risk for bleeding will be eligible for enrollment. (EGD will not be required if performed within 6 months prior to starting atezolizumab/bevacizumab combination therapy.) Patients who are deemed inappropriate by the principal investigator or study investigators to participate in this study.

研究者

相似试验

Prospective interventional clinical study to... | 临床试验